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Clinical Practice Guidelines for the Management of Atypical 
Hemolytic Uremic Syndrome in Korea
Atypical hemolytic uremic syndrome (aHUS) is a rare syndrome characterized by micro-
angiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The major 
pathogenesis of aHUS involves dysregulation of the complement system. Eculizumab, 
which blocks complement C5 activation, has recently been proven as an effective agent. 
Delayed diagnosis and treatment of aHUS can cause death or end-stage renal disease. 
Therefore, a diagnosis that differentiates aHUS from other forms of thrombotic 
microangiopathy is very important for appropriate management. These guidelines aim to 
offer recommendations for the diagnosis and treatment of patients with aHUS in Korea. 
The guidelines have largely been adopted from the current guidelines due to the lack of 
evidence concerning the Korean population.
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INTRODUCTION
Hemolytic uremic syndrome (HUS) is a syndrome characterized by microangiopathic 
hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) (1). HUS typically 
develops in children, is preceded by bloody diarrhea, and responds well to supportive 
care. Typical HUS is caused by bacterial infection associated with Shiga toxin-produc-
ing Escherichia coli (STEC) or other bacteria and is called STEC-HUS (2). However, atyp-
ical HUS (aHUS) can develop at any age; 5%-10% of cases do not have prodromal diar-
rhea and have a poor prognosis (3).
 The major pathogenesis of aHUS involves dysregulation of the complement system, 
such as genetic abnormalities or autoantibodies, which are responsible for 60%-70% of 
cases (4). Mutation in the complement factor H (CFH) gene is the most frequent cause 
of aHUS, followed by membrane cofactor protein (MCP), complement factor I (CFI), 
C3, complement factor B (CFB), thrombomodulin (THBD), and others (3,5-7). Auto-
antibodies against CFH are detected in 6%-10% of cases of aHUS (8). Recently, com-
plement-independent forms of aHUS, such as mutations in diacylglycerol kinase Ɛ 
(DGKE) and plasminogen (PLG), are reported (9).
 Eculizumab, a humanized monoclonal antibody that blocks complement C5 activa-
tion and terminal complement component formation, has recently been proven effec-
tive against aHUS (10-12). It can rescue native kidney function or allow successful kid-
ney transplantation, and may dramatically change the prognosis of this potentially fa-
tal syndrome (11).
 aHUS is often misdiagnosed as thrombotic thrombocytopenic purpura (TTP) or 
STEC-HUS, all of which show common clinical features of microangiopathic hemolytic 
anemia and thrombocytopenia. However, the pathogenesis and response rate to plas-
ma exchange (PEX) treatment differ between syndromes (13-15). Delayed treatment 
of aHUS can cause death or end-stage renal disease (ESRD) (15). Therefore, a differen-
tial diagnosis of aHUS from other forms of thrombotic microangiopathy (TMA) such 
as TTP and STEC-HUS is very important for its appropriate management.
 Since clinical trials of eculizumab with regard to aHUS began (11,12), guidelines for 
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aHUS have been developed in Europe for the standardization 
of management of aHUS (16,17). The guidelines accelerated 
the detection and clinical trials of patients with aHUS (16,18). 
However, in Korea, the diagnosis and management of aHUS 
have not been studied sufficiently due to the lack of physicians’ 
awareness and the shortage of referral diagnostic laboratories. 
Hitherto, only 26 patients with genetically confirmed aHUS are 
reported in Korea (19-21). Furthermore, aHUS management in 
Korea is in the pre-eculizumab era and needs to be improved.
 The guidelines offer recommendations for the management 
of aHUS in Korea. The guidelines’ scope includes the diagnosis 
and treatment of aHUS, with information on investigator net-
works in Korea. The guidelines were developed by the Korean 
aHUS Working Group (KHWG), which was organized to study 
aHUS in October 2015 and is composed of physicians repre-
senting the Korean Society of Pediatric Nephrology, the Korean 
Society of Nephrology, the Korean Society of Hematology, and 
the Korean Society on Thrombosis and Hemostasis as experts. 
The guidelines have largely been adopted from the current gui-
delines due to the lack of evidence concerning the Korean pop-
ulation. The GRADE system (http://www.gradeworkinggroup.
org) is used to classify the strength of the recommendations 
and the quality of the evidence (Table 1).
DISEASE OVERVIEW
Definition
HUS was earlier divided into diarrhea-positive and diarrhea-
negative HUS. The former, also referred to as typical HUS, pri-
marily results from STEC infections, and less frequently from 
other infections, including Shigella dysenteriae type 1 infection. 
All other causes of HUS are referred to as aHUS or diarrhea-
negative HUS, even though some patients with non-STEC-HUS 
also present with diarrhea (22).
 Currently, the term aHUS applies to a heterogeneous group 
of diseases that have TMA associated with some degree of AKI 
(23). TMA syndromes are united by common clinical and path-
ological features, including microangiopathic hemolytic ane-
mia, thrombocytopenia, organ injury, and vascular damage 
manifested by microvascular thrombosis (24). Three typical 
phenotypes of TMAs are STEC-HUS, aHUS, and TTP, another 
form of TMA caused by a severe deficiency of ADAMTS13 ac-
tivity.
 For aHUS, multiple underlying disease mechanisms are like-
ly involved, including increased complement activation, drugs, 
non-Shiga toxin infectious agents, cobalamin deficiency, ma-
lignancy, transplant, and autoimmune disease (23). On the ba-
sis of current diagnostic criteria, aHUS is usually defined to in-
clude all types of HUS that are unrelated to Shiga toxins. How-
ever, only HUS associated with complement dysregulation may 
be defined as aHUS as in these guidelines, because complement 
dysregulation accounts for most non-STEC cases of HUS and 
complement blockade using eculizumab should be considered 
in this group of patients (25).
 Ongoing research provides improved understanding of the 
underlying causes and new therapeutic target of HUS. The defi-
nition and nomenclature of aHUS need to be redefined based 
on the underlying pathophysiology and possible treatment op-
tions.
Incidence
The incidence of aHUS in the Korean population is not avail-
able due to a lack of data. The prevalence of aHUS in Western 
populations is thought to be approximately 2 per million in adults 
and 3.3 per million in children younger than 18 years, whereas 
the prevalence of aHUS in Japan was much lower than that of 
Western populations and was estimated as approximately 0.84 
per million population according to the Nara Medical Universi-
ty Registry (26-28). Since April 2012, when aHUS emerged at 
the global level, 681 patients have been enrolled worldwide by 
January 30, 2015 (29), and over 1,000 patients with aHUS caused 
by genetic abnormalities of the complement system are report-
ed (15,30-36).
Pathogenesis of thrombotic microangiopathy
Complement-mediated aHUS
aHUS is caused by complement dysregulation. An alternative 
complement pathway is constitutively activated and tightly reg-
ulated in normal conditions by multiple regulators to prevent 
damage to the endothelium and platelets. However, uncontrolled 
and excessive activation of this pathway, mostly due to genetic 
mutations or autoantibodies against numerous regulator pro-
teins in the complement system, occurs in patients with aHUS 
and causes various clinical manifestations (24,37). The comple-
ment cascade can cause lysis of target cells by forming a pore in 
the cell membrane. Failure of normal control mechanisms to 
downregulate the alternative pathway may cause endothelial 
damage. Complement activation triggers several inflammatory 
responses. Endothelial cells express complement receptors; 
Table 1. Strength of recommendations and quality of evidence
Definition
Level of recommendation
  1 Strong recommendation: Medical and economic benefits are definite
  2 Weak recommendation: Medical and economic benefits are suggestive of some 
benefit; the evidence is not sufficient to make a strong recommendation
Quality of evidence
  A High-quality evidence: Evidence from a meta-analysis of randomized controlled 
trials or at least one or more randomized controlled trial(s)
  B Moderate-quality evidence: Evidence from a randomized controlled study with a 
serious limitation or large-scale observational studies
  C Low-quality or very-low-quality evidence: Evidence from small-scale observa-
tional studies or nonexperimental descriptive studies such as comparative stud-
ies, correlation studies, case-control studies, or expert opinions
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they are also susceptible to complement attack. Renal cells are 
especially sensitive to complement activation, which may ex-
plain the predominance of AKI in aHUS. Von Willebrand factor 
(VWF) may activate the complement (38). Hemostatic factors 
involved in the clotting cascade, especially those with regulato-
ry roles, interact with complement proteins, but their specific 
mechanisms and roles are less well understood.
ADAMTS13-mediated TTP
TTP is caused by the severely deficient activity of the ADAMTS13 
protease, clinically defined as an activity level < 10% (39). AD-
AMTS13 cleaves VWF multimers attached to the endothelial 
surface and prevents the formation of platelet microthrombi. 
ADAMTS13 deficiency is caused by acquired autoantibodies to 
ADAMTS13 or hereditary ADAMTS13 gene mutations. The his-
topathology of TTP and other primary TMAs is characterized 
by small vessel changes, including swelling of endothelial cells 
and the subendothelial space, along with vessel wall thickening 
and platelet microthrombi, typically in small arterioles and cap-
illaries (40). Renal and central nervous system involvement is 
common.
Other types of TMA
Recently, complement-independent forms of aHUS, such as 
mutations in DGKE and PLG, have also been reported (9,24). 
The implicated factors are generally negative regulators of co-
agulation or fibrinolysis that also cross-talk with complement 
factors. Affected individuals generally present during infancy or 
early childhood. Recessive mutations in the gene encoding 
DGKE or intronic DGKE mutation (c.888+40A>G) have been 
reported in familial TMA. Homozygous or compound hetero-
zygous mutations may be seen. DGKE is expressed in endothe-
lium, platelets, and podocytes. Because DGKE is a control en-
zyme that inactivates the diacylglycerol (DAG) signaling path-
way, which promotes thrombosis, loss of DGKE function results 
in endothelial injury, podocyte dysfunction, thrombosis, AKI, 
and aHUS (9,41). Four variants in PLG (c.112 A>G, p.Lys38Glu; 
c.2134 G>A, p.Gly712Arg; c.758 G>A, p.Arg253His; c.505 C>T, 
p.Pro169Ser) are associated with aHUS (42). Because plasmin 
is able to disintegrate formed platelet aggregates, reduced pro-
teolytic activity of plasmin may result in a prethrombotic state 
of aHUS development (43).
 TMA has been reported in individuals with mutations in the 
gene encoding methylmalonic aciduria and homocystinuria 
type C (MMACHC) (44). Homozygosity or compound hetero-
zygosity appears to be required for clinical disease. MMACHC 
is involved in cobalamin (vitamin B12) metabolism. Infants with 
cobalamin C disease, a type of methylmalonic acidemia, pres-
ent with various neurologic and developmental findings. The 
patients show markedly elevated plasma homocysteine levels, 
but plasma cobalamin levels are normal. Hyperhomocystein-
emia-induced damage to glomerular endothelium has been 
suggested as the putative mechanism for aHUS (45). Complete 
responses of this TMA to the accessible and inexpensive thera-
py with high-dose cobalamin and folinic acid have been report-
ed. Evaluation of these abnormalities in cobalamin metabolism 
is available by measuring serum homocysteine and methylma-
lonic acid levels.
 Drug-induced TMA (DITMA) has been reported following 
exposure to several types of drugs, especially those containing 
quinine. Drug-induced antibodies reactive with endothelial 
cells and possibly margination of granulocytes in renal glomer-
uli may be responsible for aHUS (46).
Etiology
Defective complement regulation by mutations or autoantibo-
dies is responsible for 60%-70% of cases of aHUS (Fig. 1) (19,24, 
37). aHUS can occur due to a mutation in one of the several genes 
encoding complement factors. CFH, CFI, CFB, C3, THBD, and 
MCP have been implicated.
 CFH mutations are the most common abnormality accord-
ing to registry data from the United States and Europe and ac-
count for approximately 23%-27% of the mutations (31,47). Along 
with genetic mutations causing decreased CFH activity, 6%-10% 
of patients develop anti-CFH antibodies (48). CFH autoanti-
bodies impair the regulatory function of the complement sys-
tem by inhibiting the binding of CFH to C3b. Some cases have a 
coexisting complement gene mutation, and large deletion of 
the CFHR1 and CFHR3 genes are associated with the develop-
ment of auto anti-CFH-associated aHUS.
 MCP gene mutations are responsible for 5%-7% of aHUS 
cases, whereas the CFI and C3 gene have also been reported to 
occur at frequencies of 4%-8% and 2%-7%, respectively (31,47). 
Up to 12% of patients with aHUS have combined mutations, 
usually CFH with CFI or MCP (15). Interestingly, the incidence 
of anti-CFH antibody is demonstrated to be higher (29.7%) in a 
recent multicenter cohort study of 51 Korean children with aHUS 
(Fig. 1) (19).
Fig. 1. Etiology of atypical hemolytic uremic syndrome (aHUS) in a Korean pediatric 
cohort.
Group C (neither positive)
n = 25 (49.0%)
Group A (anti-CFH positive)
n = 15 (29.4%):
Group B (mutation positive)
n = 11 (21.6%)
CFH mutation 6
CD46/MCP mutation 2
CFI mutation 1
DGKE mutation 1
Dual gene mutations 1
   (CFH and CFI mutations)
n = 51
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 Heterozygous mutations may be sufficient to cause clinical 
manifestations. As most genes associated with aHUS showed 
incomplete penetrance, an additional trigger such as infection, 
drugs, autoimmune disease, vaccination, pregnancy, cancer, or 
transplantation is necessary to develop full clinical manifesta-
tions of aHUS in a patient with a mutation of these genes (31,49-
53). Therefore, even in patients with combined genetic muta-
tions, the clinical syndrome may not develop until middle age 
(53).
 Several other disorders such as autoimmune diseases, malig-
nancies, drugs, eclampsia or pregnancy associated HELLP syn-
drome can also cause clinical and pathological features of HUS 
and should be considered as possible alternative causes or trig-
gering factors of aHUS. However, some of these disorders are 
likely to provoke TMA directly in which effective treatment of 
disorders often leads to complete resolution of TMA (24).
 Despite substantial advances in identifying defects in the 
complement regulation, 35% to 40% of cases of aHUS are still 
classified as “idiopathic” because no demonstrable genetic 
mutations have been found (4). Whether these patients have 
no complement abnormalities or unknown genetic mutations 
of the complement system remains unknown at present.
Clinical presentations and prognosis
Common symptoms of aHUS include gastrointestinal phenom-
ena such as abdominal pains or diarrhea, although it should be 
noted that such symptoms may be insufficient to differentiate 
aHUS from typical HUS. Nonimmunologic microangiopathic 
hemolytic anemia and thrombocytopenia are the most com-
mon clinical manifestations, which ultimately affect the kid-
neys and brain, leading to acute renal failure and neurologic 
abnormalities such as confusion or convulsion. The disease 
may also invade the cardiovascular system, resulting in cardiac 
failure, myocarditis, and distal gangrene. The most common 
sequelae resulting from aHUS are chronic renal failure and hy-
pertension (54). Upper respiratory tract symptoms are also 
commonly observed. aHUS may occur secondarily in patients 
with malignant hypertension, during pregnancy, after trans-
plantation, with malignant diseases, or while using drugs such 
as anti-cancer chemotherapy or immunosuppressants (31). 
aHUS recurs frequently and its prognosis is poor, with death 
rates as high as 25% and progression to end-stage renal disease 
in 50% (3). Its rate of recurrence and prognosis vary depending 
on which particular complement mutation or environmental 
factors are present.
DIAGNOSIS
Clinical diagnosis
The diagnosis of complement-mediated aHUS is made by ex-
cluding other forms of TMA. Therefore, aHUS is suspected in 
patients with TMA without a secondary cause and ADAMTS13 
activity > 10%, without evidence of STEC-HUS (grade 1B).
 aHUS is clinically defined by the triad of microangiopathic 
hemolytic anemia, thrombocytopenia, and AKI, which should 
not be related to coexisting diseases (12,17,25,55). However, 
STEC infection can trigger an aHUS episode in approximately 
1% of patients with a complement mutation (mostly MCP mu-
tation in children) (56), and the alternative complement path-
way can be transiently activated during the acute phase of STEC-
HUS (57,58).
 The definitions of microangiopathic hemolytic anemia, throm-
bocytopenia, and AKI are summarized in Table 2 (25,31,59,60). 
However, regarding the urgency of the diagnosis and manage-
ment of aHUS, a probable diagnosis of aHUS can be made with 
two essential criteria of microangiopathic hemolytic anemia 
and thrombocytopenia, without AKI, in which case the disease 
should not be related to Shiga toxins or TTP. The diagnostic sen-
sitivity of aHUS would be increased if the data from multiple 
time points were evaluated, which would help in the early diag-
nosis and appropriate treatment of aHUS (25).
 Additionally, aHUS should also be strongly suspected if the 
following conditions are present in patients with HUS: very 
young age at onset (< 6 months); time point of HUS onset is not 
definite; recurrent HUS; recurrent HUS after renal transplanta-
tion; familial HUS; no history of diarrhea or bloody stools; and 
low C3 levels (25).
Recommendations
aHUS is suspected in patients with TMA without a secondary 
Table 2. Definitions of micro-angiopathic hemolytic anemia, thrombocytopenia, and AKI
Diagnosis Definition
Micro-angiopathic  
   hemolytic anemia
Definition of anemia: hemoglobin level < 10 g/dL
Definition of micro-angiopathic hemolysis:
   1. Increased serum LDH levels
   2. Decreases in serum haptoglobin levels
   3. Presence of red blood cell fragments in a peripheral blood smear
Thrombocytopenia Platelet count < 150 × 109/L
AKI Definition is suggested by international guidelines (KDIGO, RIFLE, and AKIN classifications)
Definition of AKI in children: Serum creatinine should be increased to a level that is 1.5-fold higher than reference values, according to age and sex
LDH, lactate dehydrogenase; AKI, acute kidney injury; KDIGO, kidney disease improving global outcomes classification; RIFLE, risk, injury, failure, loss, end-stage kidney disease 
classification; AKIN, acute kidney injury network classification.
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cause and ADAMTS13 activity over 10%, without evidence of 
STEC-HUS (grade 1B).
Distinguishing aHUS from STEC-HUS: Shiga toxin test
STEC-HUS is accompanied by bloody diarrhea due to STEC in-
fection. However, a diagnosis of STEC-HUS should not be made 
by the diarrhea symptom alone, because diarrhea can also be 
found in some patients with aHUS and asymptomatic shedding 
of STEC infection is possible (25). Therefore, tests for Shiga tox-
in/enterohemorrhagic Escherichia coli (EHEC) to exclude STEC-
HUS should be performed for all patients suspected of having 
aHUS (grade 1B).
 Various methods can be used to confirm the presence of Shi-
ga toxins in stool specimens. A stool or rectal swab should be 
performed at admission, and the specimens should be sent to 
the laboratory as soon as possible for STEC culture and Shiga 
toxin testing. If the stool specimens cannot be processed im-
mediately, they should be refrigerated until they can be tested. 
A stool culture for STEC can be performed using sorbitol Mac-
Conkey agar for O157:H7 and selective media for non-O157 
STEC (12).
 Nonculture assays can be performed to detect Shiga toxins 
such as STEC immunoassays using commercial kits, whereas 
real-time polymerase chain reaction (PCR) assays can be used 
to detect the stx1 and stx2 genes (61-63) and serum anti-lipo-
polysaccharides antibodies against common STEC serogroups 
(12).
 Although sensitivity and specificity of immunoassays approv-
ed by the Food and Drug Administration (FDA) for the diagno-
sis of Shiga toxin producing STEC infection are 92%-100% and 
98%-100%, respectively (64-67), one report demonstrated the 
superiority of PCR over EIA for the detection of STEC (68). It 
suggested that the level of detection for the EHEC enzyme im-
munoassays was 106-107 CFU/mL of O157 STEC, but that PCR 
was able to detect STEC in a suspension of 102 CFU/mL (68).
Recommendations
Tests for Shiga toxin/EHEC to exclude STEC-HUS should be 
performed for all patients suspected of having aHUS (grade 1B).
Distinguishing aHUS from TTP: the ADAMTS13 test
Because the central role of ADAMTS13 protease was discov-
ered in the pathophysiology of acquired TTP (69,70), several 
studies have assessed the clinical applicability of ADAMTS13 
activity assay to attempt distinguishing aHUS from TTP (70,71). 
The results of these studies support the hypothesis that a severe 
deficiency of ADMATS13 activity is more consistent with a di-
agnosis of acquired TTP than one of aHUS. Currently, in pati-
ents without a secondary cause of TMA, ADAMTS13 activity of 
< 10% is considered to be suggestive of TTP; otherwise, a diag-
nosis of aHUS is suggested (12,17,72-74). Therefore, tests for 
ADAMTS13 activity should be performed to exclude TTP in all 
patients suspected of having aHUS (grade 1B). However, be-
cause deficiency of ADAMTS13 activity could also be observed 
in a small number of patients with aHUS, if clinical findings are 
highly suggestive of aHUS, the diagnosis of aHUS should not be 
excluded only based on the result of ADAMTS13 activity test, 
especially in the patients who do not respond to the plasma ex-
change (75,76).
 Currently, three kinds of assays are most widely used for eval-
uation of ADAMTS13 activity: immunoblotting-based assays, 
fluorescence resonance energy transfer (FRET)-based assays, 
and collagen-binding assays (CBA). To avoid erroneous results, 
the specimen for assaying ADAMTS13 activity should be col-
lected before PEX or plasma infusion using sodium citrate as 
the anti-coagulant, not EDTA. The specimen should be pack-
aged and shipped to the reference laboratory after freezing to 
preserve the enzyme activity (73).
 Biopsies may be helpful for difficult diagnostic situations. 
Regardless of whether they are clinically involved, gingiva, skin, 
and bone marrow are suggested sites for this purpose (77). The 
thrombi of TTP are typically composed of platelets and VWF 
with minimal fibrin components. Vascular or perivascular infil-
tration of inflammatory cells is rare (78,79). In contrast, the mi-
cro-thrombi of aHUS are dominantly composed of fibrin, and 
infiltration of inflammatory cells in the perivascular area is usu-
ally observed (79,80). A recent study suggested that extensive 
microvascular deposition of C5b-9 supports the diagnosis of 
aHUS or TTP with concomitant complement dysregulation 
(81). Therefore, the use of tissue biopsies could be considered 
on a case-by-case basis along with the ADMATS13 assay.
Recommendations
Tests for ADAMTS13 activity should be performed to exclude 
TTP in all patients suspected of having aHUS (grade 1B).
Distinguishing aHUS from cobalamin defect HUS
Because HUS can develop in hereditary defects in cobalamin 
metabolism, tests for plasma homocysteine, methionine, and 
methyl-malonic acid to exclude cobalamin defect HUS are rec-
ommended for all patients suspected of having aHUS (grade 2B).
Recommendations
Tests for plasma homocysteine, methionine, and methyl-malo-
nic acid to exclude cobalamin defect HUS are recommended 
for all patients suspected of having aHUS (grade 2B).
Proposed diagram to differentiate aHUS among TMAs
In patients with thrombocytopenia and MAHA, TMA could be 
suspected clinically. MAHA could be identified by hemolytic 
anemia and the presence of schistocytes on the peripheral blood 
smear. In these patients, a thorough medical history investiga-
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tion and physical examination should be conducted for a dif-
ferential diagnosis of TMAs. The first step is to exclude other 
causative clinical situations of TMA. Examples of TMA with a 
coexisting disease or condition are summarized in Fig. 2.
 Because TMA is a multisystem disease, the presence of any 
organ injury should be identified by physical examination and 
laboratory studies. The nervous, renal, and gastrointestinal sys-
tems are most frequently involved in patients with TMAs. First, 
the physical examination should be focused on neurological or 
gastrointestinal abnormalities. Previously, neurological abnor-
malities have been used to differentiate TTP from other TMAs, 
because the involvement of the nervous system was reported in 
up to 79% of patients with TTP (82-86). However, various degrees 
of neurological injury have also been observed in ADAMTS13 
nondeficient aHUS patients (3,87-89). Therefore, the clinical 
utility of neurological symptoms is somewhat limited. Similarly, 
unexplained accompanying gastrointestinal symptoms are com-
monly observed in patients with TMAs (3,90). Nevertheless, it is 
noteworthy that patients with bloody diarrhea should be exam-
ined for Shiga toxin-producing bacteria. Although renal injury 
requiring dialysis is the more frequent manifestation among 
aHUS patients, various degrees of renal impairment are also 
observed in patients with TTP (82,84,91). Other laboratory tests 
for rare conditions associated with TMAs may be helpful in dif-
ferentiating the causes of TMAs. These include disseminated 
intravascular coagulation (DIC) panel (PT, aPTT, fibrinogen, 
FDP, d-dimer, and others), autoimmune serology (FANA, ANCA), 
paroxysmal nocturnal hemoglobinuria (PNH) screening by flow 
cytometry, and human immunodeficiency virus (HIV) screen-
ing. Therefore, the following laboratory tests for rare conditions 
associated with TMAs may be helpful in differentiating the causes 
of TMAs: DIC panel, autoimmune serology, PNH screening by 
flow cytometry, and HIV screening (grade 1B).
 In patients with TMA and any organ injury of the nervous, 
renal, or gastrointestinal system, an assay for ADAMTS13 activ-
ity and Shiga toxin/EHEC should be performed (grade 1B). Pa-
tients positive for Shiga toxin or EHEC have STEC-HUS diag-
nosed. Patients with severely deficient ADAMTS13 activity of 
Fig. 2. Proposed diagram to differentiate atypical hemolytic uremic syndrome (aHUS) among thrombotic micro-angiopathies.
MAHA, microangiopathic haemolytic anaemia; TMA, thrombotic microangiopathy; DIC, disseminated intravascular coagulation; HIT, heparin-induced thrombocytopenia; CAPS, 
Catastrophic antiphospholipid syndrome; HELLP, hemolysis, elevated liver enzymes, and low platelet count syndrome; PNH, paroxysmal nocturnal hemoglobinuria; VEGF, vascu-
lar endothelium growth factor; U/A, urine analysis; HIV, human immunodeficiency virus; ADAMTS, A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, 
member 13; EHEC, enterohemorrhagic Escherichia coli; STEC, Shiga toxin-producing Escherichia coli; HUS, hemolytic uremic symdrome; TTP, thrombotic thrombocytopenic 
purpura; aHUS, atypical hemolytic uremic symdrome.
Exclude TMA with coexisting 
   disease/condition
• Transplanation
• Malignancy/cancer chemotherapy
•  Fibrin thrombosis (DIC, HIT, CAPS, 
HELLP, PNH)
•  Vasculitis of autoimmune diseases  
or infections
• S. pneumoniae sepsis
•  Drugs (calcineurin inhibitors, 
sirolimus, anti-VEGF agents)
• Malignant hypertension
• HIV infection
History & Physical exam Routine 
   labs
• Blood chemistry
• U/A
• DIC panel
• Autoimmune serology
• PNH screening
• Microbiological studies
• HIV screening
Evaluate ADAMTS13 activity & 
Shiga-Toxin/EHEC test
Identify triggering factors
• Infection
• Stress
• Flare-up of autoimmine disease
• Surgery or trauma
• Pregnancy
• Intrevenous contrast agents
• Pancreatitis
TTP aHUS
≤10% ADAMTS13 activity > 10% ADAMTS13 activity
Neurologic abnormalities
• Focal neurologic deficits
• Metal status change
• Seizure
Renal impairments
• Serum Cr↑
• eGFR↓
• Hematuria or proteinuria
Gastrointestinal symptoms
• Diarrhea±blood
• Nausea or vomiting
• Abdominal pain
OR OR
Thrombocytopenia & MAHA
Shiga-toxin/EHEC-positive
STEC-HUS
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≤ 10% have TTP diagnosed; otherwise, (> 10% of ADAMTS13 
activity) aHUS is diagnosed. Consequently, genetic screening 
for complementary abnormalities should be performed for 
aHUS patients (grade 1B).
 In patients diagnosed with aHUS, the possibility of triggering 
factors should be investigated. Even in patients with a dysregu-
lated complement system, the clinical syndrome may not de-
velop until middle age (3). Certain clinical situations may pro-
mote the activation of the complement system and, consequent-
ly, the clinical manifestation of aHUS may develop in unaffect-
ed healthy carriers. Typical examples include infection, stress, 
active inflammation, surgery, pregnancy, and intravenous con-
trast agents (74). Any identified triggering factor should be erad-
icated as soon as possible. To prevent recurrent episodes, pa-
tients with aHUS should be educated to avoid the identified 
triggering factors as much as possible after achieving clinical 
remission (grade 1C).
Recommendations
Genetic screening for complementary abnormalities is recom-
mended for aHUS patients (grade 1B). To prevent recurrent ep-
isodes, patients with aHUS should be educated to avoid the iden-
tified triggering factors as much as possible after achieving clin-
ical remission (grade 1C).
Further investigation: genetic screening
Abnormalities of the complement regulation system are the 
main causes of aHUS and include various kinds of mutations 
and copy number variations in the genes encoding C3, CFH, 
CFI, CD46 (MCP), CFB, THBD, and complement factor H-re-
lated proteins 1 through 5 (CFHR1-5) or anti-CFH antibodies 
(12,92). Currently, 60%-70% of patients with aHUS have identi-
fiable mutations in complement genes or anti-CFH antibodies 
(4,93).
 First, serum C3 and C4 levels should be measured for all pa-
tients presenting with clinical features of HUS. If those levels 
have decreased, then aHUS should be suspected, although the 
C3 and C4 levels may be normal in aHUS. If possible, one should 
measure factor H and factor I levels in serum and CD46 expres-
sion in PBMCs using FACS, if possible, for all patients present-
ing clinical features compatible with a diagnosis of aHUS, be-
cause the results guide the prognosis and transplantation op-
tions (12,17,92). Similarly, however, normal levels or expression 
of factor H, factor I, and MCP do not rule out the possibility of a 
normally expressed but functionally impaired mutant. There-
fore, screening for complementary abnormalities by measuring 
serum levels (C3, C4, CFH, CFI, CFB, anti-CFH antibody) and 
expression of MCP in peripheral blood mononuclear cells using 
flow cytometry should be performed for aHUS patients (grade 
2B).
 Eventually, the full genetic analysis is recommended for all 
patients with aHUS who show no causative disease, STEC in-
fection, severe ADAMTS 13 deficiency, or hyperhomocystein-
emia/methyl-malonic aciduria (grade 1B) (12). Additionally, 
genetic screening should be performed without delay if the pa-
tients have an HUS relapse, a familial history of nonsynchro-
nous HUS, pregnancy/postpartum HUS, or de novo post-trans-
plant HUS (12). Genetic screening is especially essential before 
renal transplantation for aHUS. However, genetic screening is 
not justified before transplantation for STEC-HUS, unless this 
diagnosis is uncertain or unproven (12).
 There are several reasons for performing a genetic analysis 
when the first episode of aHUS occurs. First, through genetic 
analysis, we can confirm whether aHUS is complement-depen-
dent, which might predict prognosis, the risk of relapses, and 
progression to ESRD according to the results of genetic abnor-
malities and might guide the complement blockade treatment. 
Second, we can provide genetic counseling to parents and fam-
ily. Third, we can make decisions for various renal transplanta-
tion situations, such as the choice of donor, treatment guidance 
for the prevention or treatment of post-transplant recurrence, 
and whether to opt for combined kidney and liver transplanta-
tion (12).
 For genetic analysis, screening for mutations in CFH, CFI, 
MCP, C3, CFB, THBD, and DGKE should be performed by di-
rect Sanger sequencing analysis or next-generation sequencing 
(NGS), and screening for the CFH hybrid gene and copy num-
ber variation in CFH and CFHRs should be performed by mul-
tiplex ligation-dependent probe amplification (MLPA) (17). 
Additionally, because 6%-10% of aHUS patients have antibod-
ies that bind to the C terminal region of factor H, and because 
the prevalence of anti-CFH in Korean children is higher than in 
other countries (8,19), autoantibodies against factor H should 
be performed in an appropriately accredited laboratory (94).
Recommendations
Screening for complementary abnormalities measuring serum 
levels (C3, C4, CFH, CFI, CFB, anti-CFH antibody) and expres-
sion of MCP in peripheral blood mononuclear cells using flow 
cytometry should be performed for aHUS patients (grade 2B).
MANAGEMENT
Supportive treatment
Any patient suspected of having aHUS should be transferred to 
a specialized center where dialysis and PEX facilities are avail-
able. Platelet transfusion is contraindicated unless the patient is 
bleeding or when a surgical procedure carrying a risk of bleed-
ing is necessary. The protection of peripheral and central veins 
is important in patients with aHUS who need long-term vascu-
lar access for hemodialysis or PEX. Infections can trigger the re-
lapse of aHUS, and appropriate treatment is necessary (92).
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Plasma therapy
All patients who are clinically suspected of having aHUS should 
be offered a trial of PEX and/or plasma infusion (PI) as early as 
possible (17,31,92). Since the laboratory findings including com-
plement and ADAMTS13 are usually not available when the 
patient presents with clinical symptoms of aHUS, the guide-
lines recommend plasma therapy to be started within 24 hours 
of presentations including renal insufficiency, unexplained 
thrombocytopenia and a microangiopathic hemolytic anemia 
with a normal international normalized ratio and partial throm-
boplastin time. PEX is an alternative option if eculizumab is not 
available, with an exchange of 1.5 plasma volumes (60-75 mL/
kg) per session and with fresh-frozen plasma (FFP) for com-
pensation. When PEX cannot be performed, PI (10-20 mL/kg) 
should be administered. Patients receive PEX or PI daily from 5 
days up to 2 weeks during the acute phase until the platelet 
count, lactate dehydrogenase (LDH), and hemoglobin levels 
have normalized and the renal function shows signs of improve-
ment. When disease activity is controlled by daily PEX, the sub-
sequent frequency is 5 times per week for 2 weeks, and then 3 
times per week for the subsequent 2 weeks (92). The frequency 
may be reduced from weekly to every 2 to 4 weeks as a long-
term maintenance therapy. A Recent study suggested that the 
risk of ESRD after the first episode of aHUS was similar in the 
group with low-intensity plasma therapy and those with the 
high-intensity plasma therapy. Although the intensity of plasma 
therapy remains questioned, there is a clinical need for a more 
efficient treatment in patients with aHUS because of severe re-
nal outcomes (56). The further frequency of plasma therapy has 
to be decided according to the genetic information and clinical 
response to plasma therapy. In patients with an MCP/CD46 
mutation, the withdrawal of plasma therapy is possible because 
MCP is not a circulating protein. An attempt to withdraw plas-
ma therapy can be considered in patients without a relapse of 
HUS, despite tapering of PEX/PI to monthly administration 
(92). Although PEX/PI induced remission in 55%-80% of epi-
sodes in patients with aHUS in the Italian cohort, 48% of chil-
dren and 67% of adults died or progressed to ESRD during the 
3-year follow-up period (31).
Recommendations
All patients who are clinically suspected of having aHUS should 
be offered a trial of PEX and/or PI if eculizumab is not available 
(grade 1C).
Kidney transplantation
The risk of HUS recurrence after kidney transplantation varies 
according to the underlying genetic abnormality. Renal trans-
plantation alone is not recommended for patients with a CFH 
or CFI mutation because of the poor outcome, with 80% of pa-
tients losing their graft due to a recurrence of the disease within 
2 years. In patients with an MCP/CD46 mutation alone, the risk 
of recurrence post-transplantation is low. Patients with a C3 or 
CFB mutation show a significant risk of disease recurrence post-
transplantation. No post-transplantation recurrence has been 
observed to date in patients with a DGKE mutation. Patients 
with an anti-factor H autoantibody should be treated with a 
PEX combination with Rituximab to minimize the antibody ti-
ter before proceeding to renal transplantation (17). Living-re-
lated renal transplantation alone should be avoided in cases of 
aHUS (12,17,92). PEX/PI for post-transplant recurrence usually 
failed to prevent graft loss, and prophylactic PEX/PI was recom-
mended. According to the Consensus Study Group, one PEX 
with FFP (60-75 mL/kg) should be performed within 4-6 hours 
before graft reperfusion, FFP (10-20 mL/kg) should be infused 
during surgery, and PEX with FFP (60-75 mL/kg) should be 
continued daily for at least 5 days, followed by 5 sessions per 
week for 2 weeks, and then 3 sessions per week for 2 weeks, af-
ter which it should be tapered on a case-by-case basis. Recent-
ly, prophylactic eculizumab treatment for patients at high risk 
for post-transplant recurrence has been considered (95).
Recommendations
Patients should be informed that the risk of disease recurrence 
after renal transplantation varies according to the causative 
mutations. Patients with an anti-factor H autoantibody should 
be treated with a PEX combination with Rituximab to minimize 
the antibody titer before proceeding to renal transplantation. 
Living-related renal transplantation alone should be avoided in 
cases of aHUS (grade 1C).
Liver transplantation
Because CFH, CFI, CFB, and C3 are synthesized in the liver, an 
isolated liver transplantation or a combined liver and kidney 
transplantation may be an option for patients with preserved 
eGFR, despite a severe and/or relapsing course, and for pati-
ents with a CFH, CFI, CFB, or C3 mutation, complications, or 
no benefit from PEX/PI and no access to eculizumab treatment 
(12,17,92,95).
Recommendations
Isolated liver or combined liver-kidney transplantation may be 
performed for patients with a CFH, CFI, CFB, or C3 mutation 
(grade 2C).
Terminal complement blockade (eculizumab)
Eculizumab has been used successfully in patients with aHUS 
since 2009 (96), and it received approval for the treatment of 
aHUS in the United States and Europe in late 2011. Eculizumab 
reduces terminal complement activation (C5b-9, membrane 
attack complex). Eculizumab therapy for patients with aHUS 
also reduces inflammation, endothelial damage, thrombosis, 
Cheong HI, et al. • Korean Guidelines for aHUS
1524  http://jkms.org http://dx.doi.org/10.3346/jkms.2016.31.10.1516
and renal injury. Therefore, eculizumab therapy reduces the 
ongoing risk of systemic TMA and progression to organ dam-
age in patients with aHUS (97).
 Eculizumab therapy for aHUS is usually delayed for several 
days because it takes several days to obtain baseline ADAMTS13 
activity results, which are necessary for the differential diagno-
sis between aHUS and TTP. However, eculizumab therapy should 
be considered as a first-line therapy for patients who already 
have had aHUS diagnosed or who have had mutation results 
for aHUS (72). Because TTP is less common in children, and 
because plasma exchange therapy is ineffective in patients with 
aHUS, it is also important to start eculizumab therapy as soon 
as possible in pediatric patients who are suspected of having 
aHUS (12).
 Because eculizumab therapy increases the risk of meningo-
coccal infections, patients should receive a meningococcal vac-
cination at least 2 weeks prior to receiving the first dose of ecu-
lizumab. However, eculizumab therapy usually cannot be de-
layed in patients with aHUS. Therefore, additional prophylactic 
antibiotics for 2 weeks (ciprofloxacin 500 mg twice daily, rifam-
pin 600 mg twice daily, or penicillin VK 250 mg four times daily) 
should be considered for patients with aHUS who are begin-
ning eculizumab therapy (72). Eculizumab therapy is usually 
initiated intravenously at a dose of 900 mg weekly for the first 4 
weeks, followed by 1,200 mg for the fifth dose 1 week later, and 
then 1,200 mg every other week thereafter. Dose adjustments 
should be considered for pediatric patients with body weight 
< 40 kg (12,72). The recommended dosage and schedule are 
summarized in Table 3 (12).
 Whereas improvement of thrombocytopenia and elevated 
LDH occur more quickly after eculizumab therapy, recovery of 
renal function and other end-organ injuries present may take 
longer. Therefore, recovery from thrombocytopenia is used as a 
surrogate marker for activity of complement-mediated TMA 
(10). With continuous therapy, a time-dependent improvement 
of the estimated GFR is usually observed. Some patients even-
tually discontinued their previous dialysis. Patients with aHUS 
who undergo eculizumab therapy have an approximately 50% 
lower risk of reaching ESRD within 3 months of an aHUS epi-
sode compared with historical controls (98). Life-long eculizu-
mab maintenance therapy is usually required for aHUS (10). If 
aHUS patients discontinue eculizumab treatment, then they 
Table 3. Recommended dosage and schedule of eculizumab in patients with aHUS
Body weight Induction period Maintenance period
≥ 40 kg 900 mg/wk × 4 doses 1,200 mg during week 5,  
   then 1,200 mg every 2 wk
From 30 kg to < 40 kg 600 mg/wk × 2 doses 900 mg during week 3,  
   then 900 mg every 2 wk
From 20 kg to < 30 kg 600 mg/wk × 2 doses 600 mg during week 3,  
   then 600 mg every 2 wk
From 10 kg to < 20 kg 600 mg/wk × 1 dose 300 mg during week 2,  
   then 300 mg every 2 wk
From 5 kg to < 10 kg 300 mg/wk × 1 dose 300 mg during week 2,  
   then 300 mg every 3 wk
aHUS, atypical hemolytic uremic syndrome.
Table 4. Recommendations for the diagnosis and management of atypical hemolytic uremic syndrome
Category Contents
Strength of recommendations 
and quality of evidence
Diagnosis aHUS is suspected in patients with TMA without a secondary cause, ADAMTS13 activity > 10%, without evidence of STEC-HUS 1B
Tests for ADAMTS13 activity should be performed for all patients with suspected aHUS 1B
The specimen for testing ADAMTS13 activity should be packaged and shipped to the reference laboratory after freezing to  
preserve the enzyme activity
1B
Tests for Shiga toxin/EHEC to exclude STEC-HUS should be performed for all patients suspected aHUS 1B
Tests for plasma homocysteine, methionine, and methyl-malonic acid to exclude cobalamin defect HUS are recommended for all 
patients with suspected aHUS
2B
Screening for complementary abnormalities measuring serum levels (C3, C4, CFH, CFI, CFB, anti-CFH antibody) and expression 
of MCP in peripheral blood mononuclear cells using flow cytometry abnormalities is recommended for aHUS patients
2B
Genetic screening for complementary abnormalities is recommended for aHUS patients 2B
Tissue biopsies could be considered on a case-by-case basis for patients with suspected aHUS 2C
Other laboratory tests for rare conditions associated with TMAs may be helpful in differentiating the causes of TMAs: DIC panel, 
autoimmune serology, PNH screening by flow cytometry, and HIV screening
1B
Management All patients who are clinically suspected of having aHUS should be offered a trial of PEX and/or plasma infusions if eculizumab is 
not available
1C
Liver-related renal transplantation alone should be avoided in cases of aHUS 1C
An isolated liver transplantation or a combined liver and kidney transplantation may be an option for patients with a CFH, CFI, 
CFB, or C3 mutation
2C
Eculizumab is recommended as a first-line treatment for patients with symptomatic aHUS 1C
All patients receiving eculizumab should receive a meningococcal vaccination prior to receiving the first dose of eculizumab 1A
To prevent recurrent episodes, patients with aHUS should be educated to avoid the identified trigger factors as much as possible 
after achieving clinical remission
1C 
aHUS, atypical hemolytic uremic syndrome; CFB, complement factor B; CFH, complement factor H; CFI, complement factor I; DIC, disseminated intravascular coagulation; EHEC, 
enterohemorrhagic Escherichia coli; HIV, human immunodeficiency virus; MCP, membrane cofactor protein; PEX, plasma exchange; PNH, paroxysmal nocturnal hemoglobinuria; 
STEC-HUS, Shiga toxin–producing Escherichia coli hemolytic uremic syndrome; TMA, thrombotic micro-angiopathy.
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should be monitored closely for signs and symptoms of severe 
complications (99). Monitoring of the complement function 
test may allow a safe reduction of eculizumab therapy when 
patients remain in sustained remission (100). However, a con-
tinuation of eculizumab therapy is recommended for kidney 
transplant recipients with CFH mutations, for anti-CFH anti-
body-positive patients with an antibody titer < 2.5-times the 
upper limit of normal, and for patients with GFR < 20 mL/min/ 
1.73 m2 (101). Because of another acute episode of aHUS after 
any complement-activating clinical event (infection, surgery, or 
pregnancy), careful monitoring and education should be em-
phasized for patients who have discontinued eculizumab.
Recommendations
Eculizumab is recommended for patients with symptomatic 
aHUS (grade 1C). All patients receiving eculizumab should re-
ceive a meningococcal vaccination prior to receiving the first 
dose of eculizumab (grade 1A).
Recommendations for the diagnosis and management of 
aHUS
The Korean aHUS Working Group suggested the recommenda-
tions for the diagnosis and management of aHUS (Table 4). Al-
though the guidelines are developed based on the current evi-
dence, there are still many limitations to apply each recommen-
dation in real clinical practice because of limited resources in 
Korea. The guidelines are not intended to limit, but improve 
current practice on the management of aHUS. Therefore, these 
guidelines intend to provide Korean physicians on the general 
information only and do not replace professional medical prac-
tice.
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